MINAJ Act of 2023

Bill: 118-hr-2631
Sponsor: full_name: Rep. Santos, George [R-NY-3]
Introduced: 2023-04-17
Policy area: Health
Latest action: action_date: 2023-04-26
text: Sponsor introductory remarks on measure. (CR H2044)

Summaries:
action_date: 2023-04-17
action_desc: Introduced in House
text: <p><b>Medical Information Nuanced Accountability Judgement Act of 2023 or the MINAJ Act of 2023</b></p> <p>This bill generally prohibits federal agencies from requiring an individual to receive a vaccine unless the required vaccine has been approved or authorized by the Food and Drug Administration for at least 10 years.</p> <p>During a declared public health emergency, however, a federal agency may require that individuals receive a vaccine with fewer years of approval or authorization if the agency provides Congress with (1) adequate notice of the requirement, (2) data about the safety and efficacy of the required vaccine, and (3) sufficient time to review the data and deliberate about the requirement. Under the bill, sufficient time for review and deliberation is the lesser of three months or the period of time during which the House Committee on Energy and Commerce and the Senate Committee on Health, Education, Labor, and Pensions each complete three hearings related to matters in the report.</p>

tv_txt: I 118th CONGRESS 1st Session H. R. 2631 IN THE HOUSE OF REPRESENTATIVES April 17, 2023 Mr. Santos introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To prohibit the Federal Government from imposing any mandate requiring an individual to receive a vaccine that has not been authorized for marketing for at least 10 years, and for other purposes.

1. Short title This Act may be cited as the Medical Information Nuanced Accountability Judgement Act of 2023 or the MINAJ Act of 2023 . 2. Prohibition against vaccine mandates prior to marketing approval for at least 10 years (a) Prohibition The Federal Government shall not establish, implement, or enforce any mandate requiring an individual to receive a vaccine that has not been authorized for marketing for at least 10 years. (b) Public health emergency exception Subsection (a) does not apply if— (1) the mandate is intended to prevent or mitigate a disease with respect to which a public health emergency declaration is in effect; and (2) the Federal department or agency seeking to impose the mandate— (A) submits a report to the appropriate committees of Congress— (i) giving notice of the intent to impose the mandate; and (ii) including all data in the possession of the department or agency on the safety and efficacy of the vaccine involved; and (B) gives the appropriate committees of Congress a sufficient period to conduct extensive review of the matters in such report. (c) Sufficient period of time For purposes of subsection (b)(2)(B), a sufficient period shall be the lesser of— (1) 3 months; and (2) the period over which the appropriate committees of Congress each complete three hearings on the matters in the report submitted under subsection (b)(2)(A). (d) Definitions In this section: (1) The term appropriate committees of Congress means— (A) the Committee on Energy and Commerce of the House of Representatives; and (B) the Committee on Health, Education, Labor, and Pensions of the Senate. (2) The term authorized for marketing means licensed, approved, or authorized under— (A) section 351 of the Public Health Service Act ( 42 U.S.C. 262 ); or (B) section 505 or 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 , 360bbb–3). (3) The term mandate includes any condition imposed on— (A) hiring or employment; or (B) the receipt of a service or benefit. (4) The term public health emergency declaration means a public health emergency declaration under section 319 of the Public Health Service Act ( 42 U.S.C. 247d ).